Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 6/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827747 | 0.92 | CAPN1 (0.38) | ADH5MKNK1MKNK2NSD2PDE4A | |
| SCHEMBL242470 | 0.83 | PLAU (0.40) | RPS6KA3CYP2C19 | |
| SCHEMBL245902 | 0.76 | MAPKAPK2 (0.41) | CYP2C19 | |
| SCHEMBL1831739 | 0.74 | EGLN2 (0.40) | ADH5NSD2PDE3BPDE3AALDH1A1 | |
| SCHEMBL242932 | 0.73 | SMN1; SMN2 (0.41) | ADH5CYP2C19 | |
| SCHEMBL13492934 | 0.73 | CAPN1 (0.34) | ADH5NSD2 | |
| SCHEMBL245768 | 0.72 | MAPKAPK2 (0.45) | MKNK1MKNK2NSD2 | |
| SCHEMBL242923 | 0.72 | PTPN11 (0.46) | ADH5 | |
| SCHEMBL243838 | 0.70 | MAPKAPK2 (0.45) | ADH5 | |
| SCHEMBL2051693 | 0.70 | ADH5 (0.45) | ADH5MKNK1MKNK2NSD2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | claimed |
| EP-2315590-B1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS LLC (US) | 2012-09-26 | — | — | EP | claimed |
| JP-2012500218-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | claimed |
| EP-2315590-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | claimed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| EP-2315590-B1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS LLC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2315590-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | ADH5 84/4885MKNK1 3925/4885MKNK2 3557/4885 |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | ADH5 84/4885MKNK1 3925/4885MKNK2 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.